证券代码：603259 证券简称：药明康德 公告编号：临 2025-063 A 股每股现金红利0.35000元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/25 | － | 2025/9/26 | 2025/9/26 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经无锡药明康德新药开发股份有限公司（以下简称"本公 司"） 2025 年 4 月 29 日的2024年年度股东大会授权董事会在符合利润分配的条件 下制定具体的中期分红方案，并经 2025 年 7 月 28 日召开的第三届董事会第二十 二次会议审议通过。 无锡药明康德新药开发股份有限公司 2025年半年度A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 ...

Core Viewpoint - The significant stock price movements in A-shares on September 19 were primarily driven by the adjustments in the FTSE China A50 Index, which took effect after the market closed on that day [1][6]. Group 1: Stock Movements - Several stocks, including Xinyi Technology, Zhongji Xuchuang, WuXi AppTec, and BeiGene, experienced notable price increases during the closing auction period [2][1]. - Conversely, stocks such as China Nuclear Power, China Unicom, and Wanhua Chemical saw substantial declines, with China Nuclear Power dropping nearly 2 percentage points [4][1]. Group 2: Index Adjustments - The FTSE Russell announced changes to the FTSE China A50 Index, which included the addition of stocks like Xinyi Technology and WuXi AppTec, while removing China Nuclear Power and China Unicom [6][1]. - The FTSE China A50 Index consists of the 50 largest stocks listed on the Shanghai and Shenzhen exchanges and undergoes quarterly reviews [6][1]. Group 3: Market Reactions - The adjustments in the FTSE indices prompted index funds and institutional investors to rebalance their portfolios, leading to the observed stock price volatility [1][6]. - The market showed a clear divergence in performance, with sectors like photolithography, lithium mining, and engineering machinery gaining strength, while others faced significant corrections [2][1]. Group 4: Broader Market Context - The overall A-share market experienced a mixed performance, with the Shanghai Composite Index down by 0.30% and the Shenzhen Component down by 0.04% [2][1]. - In the Hong Kong market, stocks such as Fourth Paradigm and SF Holding also exhibited significant movements, influenced by similar index adjustments [7][1]. Group 5: Future Outlook - Analysts suggest that the Chinese stock market may see further prosperity driven by valuation and liquidity factors, maintaining a positive outlook on both A-shares and H-shares [7][8]. - Focus areas include core growth sectors in Hong Kong, particularly in internet, innovative pharmaceuticals, new consumption, and technology [8][1].

无锡药明康德新药开发股份有限公司发布2025年半年度A股权益分派实施公告。本次利润分配方案经 2024年年度股东大会授权及第三届董事会第二十二次会议审议通过。以总股本2,951,506,736股为基数， 每股派发现金红利0.35元（含税），A股共派发现金红利865,648,086.10元（含税）。股权登记日为2025 年9月25日，除权（息）日和现金红利发放日为9月26日。不同类型股东扣税政策有别，如自然人股东和 证券投资基金暂不扣缴，QFII股东和沪股通投资者按10%税率代扣。如有疑问可联系董事会办公室，电 话021 - 20663091。 ...

Group 1 - The core point of the article highlights significant stock movements in the A-share market, with several companies experiencing sharp fluctuations during the closing auction [1] - New companies such as Baijiazhenshou-U, New Yisheng, WuXi AppTec, and Zhongji Xuchuang are being added to the FTSE China A50 Index, while companies like China Nuclear Power, China Unicom, Guodian Nari, and Wanhua Chemical are being removed [1] - The changes announced by FTSE Russell on September 3 will take effect after the market closes on September 19 [1]

Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule chemical drugs, serving global pharmaceutical companies [1][2]. Financial Performance - For the first half of 2025, WuXi AppTec achieved a revenue of 20.799 billion yuan, representing a year-on-year growth of 20.64%. The net profit attributable to shareholders was 8.561 billion yuan, showing a significant increase of 101.92% year-on-year [2]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [2]. Stock Performance - As of September 19, WuXi AppTec's stock price was 105.22 yuan per share, with a market capitalization of 310.558 billion yuan. The stock has increased by 95.90% year-to-date, with a slight decline of 0.24% over the past five trading days [1]. - The trading volume on September 19 was 3.397 billion yuan, with a turnover rate of 1.28% [1]. Shareholder Structure - As of June 30, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 56.0239 million shares from the previous period. Other notable shareholders include Huaxia SSE 50 ETF and China Europe Medical Health Mixed A [3]. Industry Classification - WuXi AppTec is classified under the pharmaceutical and biotechnology sector, specifically in medical services and contract research organization (CRO) services. The company is associated with concepts such as cell therapy, precision medicine, innovative drugs, and overseas expansion [2].

Group 1 - The core transaction of WuXi AppTec occurred on September 18, with a volume of 50,000 shares and a transaction amount of 5.3715 million yuan, at a price of 107.43 yuan per share [2] - In the last three months, WuXi AppTec has had a total of four block trades, amounting to 38.301 million yuan [3] - The closing price of WuXi AppTec on the same day was 107.43 yuan, reflecting a decrease of 1.70%, with a turnover rate of 2.20% and a total trading volume of 5.895 billion yuan [3] Group 2 - The latest margin financing balance for WuXi AppTec is 5.966 billion yuan, which has decreased by 162 million yuan over the past five days, representing a decline of 2.65% [4] - The net outflow of main funds for WuXi AppTec on that day was 207 million yuan, while the stock has seen a cumulative increase of 2.66% over the past five days, with a total net inflow of 32.3834 million yuan [3]

Group 1 - WuXi AppTec's stock closed down 1.70% on September 18, with a closing price of 107.43 yuan [1] - A block trade occurred with a total volume of 50,000 shares and a transaction amount of 5.3715 million yuan, with a premium rate of 0.00% [1] - The buyer was Huatai Securities Co., Ltd., and the seller was Guotai Junan Securities Co., Ltd. [1] Group 2 - In the last three months, WuXi AppTec has had a total of four block trades, with a cumulative transaction amount of 38.301 million yuan [1] - Over the past five trading days, the stock has increased by 2.66%, with a net inflow of main funds totaling 12.6333 million yuan [1]

Investment Rating - The report maintains an investment rating of "Outperform" for the pharmaceutical and biotechnology industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical and biotechnology industry is experiencing a recovery in Q2 2025, with innovative drugs poised for significant development opportunities [1][10]. - The overall revenue for 461 A-share pharmaceutical companies in H1 2025 was CNY 11,939.5 billion, a year-on-year decrease of 3.21%, while net profit attributable to shareholders was CNY 1,016.2 billion, down 8.55% [8][24]. - The medical services sector showed positive growth, with revenue increasing by 3.92% year-on-year, while other segments like raw materials, chemical preparations, traditional Chinese medicine, and medical devices faced declines [8][24]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index rose by 7.36% in H1 2025, outperforming the CSI 300 index by 7.33 percentage points, with the chemical preparation sector leading with a 20.09% increase [15][21]. 2. Industry Performance - In H1 2025, the chemical preparation sector reported a revenue of CNY 2,044.3 billion, down 5.77%, and a net profit of CNY 223.1 billion, down 22.92% [43]. - The medical services sector achieved a revenue of CNY 890.2 billion, with a significant net profit increase of 40.22% [8][24]. - The report highlights a trend of improving performance in Q2 compared to Q1, with several sectors showing signs of recovery [30]. 3. Subsector Analysis Raw Materials - The raw materials sector generated CNY 459.1 billion in revenue, a decrease of 6.74%, with a net profit of CNY 45.4 billion, down 2.71% [32][38]. - The report suggests a long-term growth outlook for the raw materials sector, driven by increasing demand and regulatory changes [38]. Chemical Preparations - The chemical preparations sector is expected to benefit from new policies supporting innovative drugs, with a focus on balancing price and clinical needs [48][49]. - The sector's revenue and profit are under pressure but are anticipated to recover as innovation and reform take hold [43][48]. Traditional Chinese Medicine - The traditional Chinese medicine sector reported a revenue of CNY 1,731.95 billion, with a slight profit increase of 0.24% [52]. - The sector is seen as having structural opportunities despite overall revenue declines [52]. Medical Services - The medical services sector is highlighted for its robust growth, with a focus on integrated service platforms [30][31]. Medical Devices - The medical devices sector is expected to recover as demand for equipment updates increases, with a revenue of CNY 1,155.6 billion, down 4.47% [8][30]. 4. Recommendations - The report recommends focusing on leading companies in various sectors, such as Tianyu Co. in raw materials, BeiGene in innovative drugs, and Yifeng Pharmacy in medical commerce [8][42][50].

Group 1 - The core viewpoint of the news highlights the significant stock performance and financial growth of WuXi AppTec, with a year-to-date stock price increase of 103.39% and a market capitalization of 322.43 billion yuan [1][2] - WuXi AppTec's main business segments include small molecule chemical drug discovery, research and production services, with revenue contributions of 78.37% from chemical services, 12.93% from testing services, and 6.02% from biological services [1][2] - The company reported a revenue of 20.64% year-on-year growth, reaching 20.799 billion yuan for the first half of 2025, and a net profit increase of 101.92%, amounting to 8.561 billion yuan [2] Group 2 - As of June 30, 2025, the second-largest shareholder of WuXi AppTec is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 5.602 million shares from the previous period [3] - The seventh-largest shareholder is Huaxia SSE 50 ETF, with 48.998 million shares, an increase of 3.2196 million shares [3] - The eighth-largest shareholder is China Europe Medical Health Mixed A, holding 46.0291 million shares, which decreased by 0.0754 million shares [3]

Summary of CXO Industry and Company Insights Industry Overview - The CXO sector demonstrated exceptional performance in the first half of 2025, with revenue growth of approximately 15% year-on-year and a scale growth exceeding 60% [1][5] - The CDMO industry benefited from increased capital expenditures and improved capacity utilization, leading to a non-GAAP net profit growth of 26%, significantly outpacing revenue growth [1][5] - The overseas CDMO companies saw a notable improvement in orders in the second and third quarters of the previous year, translating to a revenue growth of around 20% in the first half of this year [6] Key Insights - WuXi AppTec contributed over 40% of the CXO sector's revenue and more than 60% of its profits, serving as a major growth driver [1][5] - The gross profit margin for overseas businesses is significantly higher than domestic counterparts, with an increase in capacity utilization further enhancing profitability [6] - The trend of overseas biopharmaceutical investment and financing is negatively correlated with the Federal Reserve's interest rates, with a 20% increase in quarterly average investment amounts compared to 2021 [7][8] Domestic Market Dynamics - The domestic innovative drug R&D landscape is on an upward trend, with increased funding availability and improved channels for capital sourcing [9] - The resurgence of IPOs in the Hong Kong market reflects an improved capital environment, which is expected to sustain the growth of domestic innovative drug R&D [2][10] - The A-share market's allowance for unprofitable companies to list has significantly expanded the fundraising capabilities of pharmaceutical companies, enhancing their cash reserves [11] Financial Performance - The overall performance of the innovative drug industry chain, including CRO and life sciences services, showed approximately 10% revenue growth in both the first and second quarters of 2025, with profits exceeding revenue growth [3][4] - The CRO companies, such as Kanglong Chemical and Hongbo Pharmaceutical, returned to double-digit revenue growth in the first half of the year [16] - The clinical phase CRO companies experienced a smaller decline in performance compared to the preclinical phase, with improving orders and revenue expected to enhance overall industry performance in the latter half of the year [18] Investment Trends - The second quarter saw external BD upfront payments become a significant and reliable source of R&D funding, exceeding twice the amount of China's biopharmaceutical investment and financing [12] - The biopharmaceutical investment market in China showed signs of recovery, with significant improvements in funding levels observed in July and August [13] - The new BD business model has shifted focus towards early-stage clinical projects, increasing the proportion of early R&D investments compared to previous years [14][15] Conclusion - The CXO sector and innovative drug R&D in China are poised for growth, driven by improved capital conditions, increased funding sources, and a favorable investment environment. The performance of key players like WuXi AppTec highlights the potential for continued success in this dynamic industry [1][9][10]